In this article, we will take a look at some of the best stocks to buy for the long term.
Dividend stocks offer solid investment options when it comes to long-term investing. A report by Hartford Funds revealed that from 1960 through 2023, 85% of the market’s cumulative total return can be attributed to reinvested dividends and the power of compounding. The report also highlighted that from 1940 to 2024, dividend income made up nearly 34% on average of the total return of the S&P 500.
Dividend stocks have faltered this year in comparison to the market because of the growing appeal of AI stocks. However, all hope is not lost as the Federal Reserve may cut interest rates for the third time this year, which could reduce the appeal of income-generating assets, such as CDs, money market funds, and US Treasuries. This could result in declining yields on these alternatives. For this reason, investors seeking steady income may increasingly turn to dividend-paying stocks.
Christine Benz, Morningstar’s director of personal finance and retirement planning, is a strong supporter of dividend stocks. In her August interview on The Morning Filter podcast, she emphasized their value in building a well-rounded investment portfolio. Here are some of her comments:
“Once you are separated from your paycheck, the idea of having stable sources of income or semistable sources of income is very, very appealing. Then the other thing I would point to is that dividend-paying companies typically are more financially stable than non-dividend-paying companies. There is a sense of financial wherewithal that you get from a dividend-payer. And then when we look at the historical data, we also see that dividend-payers have historically been a little bit less volatile, especially in periods of economic weakness, than companies that do not pay dividends.”
Given this, we will take a look at some of the best stocks to buy for the long term.
Our Methodology
For this article, we screened for companies with a market cap of at least $2 billion, with strong dividend histories and sound financials. From that list, we identified companies with positive revenue growth over the past five years and shortlisted those that have a 5-year average annual revenue growth of over 5%. From that group, we picked 15 companies that were most popular among hedge funds, as per Insider Monkey’s database of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
15. Badger Meter, Inc. (NYSE:BMI)
Number of Hedge Fund Holders: 28
5-Year Revenue Growth: 15.22%
Badger Meter, Inc. (NYSE:BMI) is one of the best stocks to buy for the long term.
On December 8, JPMorgan lowered the firm’s price target on Badger Meter, Inc. (NYSE:BMI) to $235 from $240 and maintained an Overweight rating on the shares. The update came as part of the firm’s 2026 outlook on the clean energy market. JPMorgan expects another year of strong performance for utility-scale projects in the renewables space, though it sees the market shifting toward larger, more complex projects and tougher regulations, which could lead to more consolidation. The analyst said they still prefer companies with US manufacturing, diverse customers, and solid balance sheets.
On November 7, Badger Meter, Inc. (NYSE:BMI) declared a quarterly dividend of $0.40 per share, which was consistent with its previous dividend. In addition, the Board approved a new share repurchase authorization for up to $75 million of the company’s outstanding common stock through November 2028. This new program would enable the company to purchase shares from time to time in the open market. In its press release, the company declared that it has been returning value to shareholders through growing dividends for 33 consecutive years.
Badger Meter, Inc. (NYSE:BMI) is an American company that specializes in flow measurement, water quality, and control products, serving water utilities and other commercial customers.
14. Brunswick Corporation (NYSE:BC)
Number of Hedge Fund Holders: 38
5-Year Revenue Growth: 6.77%
Brunswick Corporation (NYSE:BC) is among the best stocks to buy for the long term.
On December 8, Seaport Research initiated its coverage on Brunswick Corporation (NYSE:BC) with a Buy rating and a $90 price target. The analyst, in the research note, highlighted that Brunswick is the largest producer of recreational marine products, noting that the marine market is highly cyclical and now is the right moment to step in. The firm expects the industry to pick up in 2026 as consumers increase their discretionary spending on leisure items like boats and engines.
In the third quarter of 2025, Brunswick Corporation (NYSE:BC) reported growth in its business despite a challenging macro environment and industry backdrop. The company’s revenue of $1.36 billion surged by 6.8% from the same period last year. Its boat retail sales were flat YoY, which showed a comparative progress from the first half of the year. Freedom Boat Club contributed approximately 13% of segment sales.
Brunswick Corporation (NYSE:BC)’s financial performance remained strong, which enabled the company to invest in its business, return value to shareholders, and strengthen its balance sheet. The company’s free cash flow of $111 million in Q3 brought its year-to-date free cash flow to $355 million. Due to this strong cash flow, Brunswick completed $70 million of share repurchases YTD and also boosted its debt reduction target to $200 million.
Brunswick Corporation (NYSE:BC) is an Illinois-based boat-building company that manufactures and markets a wide variety of related products.
13. Becton, Dickinson and Company (NYSE:BDX)
Number of Hedge Fund Holders: 41
5-Year Revenue Growth: 5.55%
Becton, Dickinson and Company (NYSE:BDX) is one of the best stocks to invest in for the long term.
On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s MedTech “looks well-positioned on several fronts.” The firm also thinks that major product cycles, healthier hospital spending, and valuations near their lows all signal a supportive setup for the industry in the year ahead.
In its earnings for fiscal Q4 2025, Becton, Dickinson and Company (NYSE:BDX) announced that the merger of its Biosciences and Diagnostic Solutions, which the company separated and refers to as New BD, with Waters Corporation will be completed around the end of the first quarter of 2026. New BD will be a MedTech company with far-reaching influence on patients and healthcare worldwide. In FY25, New BD reported revenue of $17.5 billion, compared with $16.8 billion in the prior-year period.
Becton, Dickinson and Company (NYSE:BDX)’s overall revenues for Q4 were $5.9 billion, which showed an 8.3% growth YoY. The company’s cash and cash equivalents at the end came in at $641 million, and operating cash flow was $3.4 billion in 2025. Becton returned $2.2 billion to investors in dividends and share repurchases, exhibiting its commitment to returning value to shareholders.
Becton, Dickinson and Company (NYSE:BDX) is an American multinational medical technology company that manufactures and sells essential medical devices and related products.
12. Church & Dwight Co., Inc. (NYSE:CHD)
Number of Hedge Fund Holders: 44
5-Year Revenue Growth: 6.36%
Church & Dwight Co., Inc. (NYSE:CHD) is one of the best stocks to buy for the long term.
On December 4, Argus lowered its price target on Church & Dwight Co., Inc. (NYSE:CHD) to $102 from $110 but maintained a Buy rating on the shares. The firm mentioned that, as Consumer Goods names faced broader weakness, CHD also underperformed. However, the analyst noted that the management’s renewed emphasis on its leading brands could help capture market share and support an expected 8% annual EPS growth.
In its earnings for the third quarter of 2025, Church & Dwight Co., Inc. (NYSE:CHD) reported that the company’s categories are growing at around 2% despite a volatile macro environment. CEO Richard Dierker attributed this growth to the company’s balanced value, ongoing innovation, and premium portfolio. He also highlighted the July purchase of TOUCHLAND, defining it as the fastest-growing hand sanitizer brand in the US, and pointed out its double-digit consumption growth.
Church & Dwight Co., Inc. (NYSE:CHD), in the third quarter of 2025, reported revenue of $1.6 billion, which grew by 5% from the same period last year. The revenue surpassed analysts’ estimates by $49.8 million. The company’s organic sales grew by 3.4% and its domestic and international sales surged by 2.3% and 7.7%, respectively. Church & Dwight demonstrated a stable cash position, recording a 19.6% YoY growth in its operating cash flow at $435.5 million.
Church & Dwight Co., Inc. (NYSE:CHD) is an American manufacturing company that specializes in consumer goods products, including personal care, household products, and specialty products.
11. Albemarle Corporation (NYSE:ALB)
Number of Hedge Fund Holders: 45
5-Year Revenue Growth: 19.82%
Albemarle Corporation (NYSE:ALB) is one of the best stocks to buy for the long term.
UBS upgraded Albemarle Corporation (NYSE:ALB) to Buy from Neutral on December 5, and also raised its price target to $185 from $107. The update came as the firm expects growing energy storage demand, coupled with years of slower capacity expansion in the West, to create a lithium market deficit by 2026. Rising lithium prices throughout the year are expected to boost ALB’s stock, and UBS now sees a supply shortfall in the second half of 2026.
Albemarle Corporation (NYSE:ALB) reported strong earnings in the third quarter of 2025, despite a weak lithium price environment. The company posted net sales of $1.3 billion, including an 8% YoY growth in Energy Storage. Adjusted EBITDA came in at $226 million, which grew by 7% due to ongoing cost savings. These results were encouraging to investors as the management also highlighted its cost-cutting actions and divestitures.
As part of its cost-cutting efforts, Albemarle Corporation (NYSE:ALB) reduced its capital expenditures to $434 million in the first nine months of the year, compared with $903 million in the same period last year. Moreover, the company expects CapEx to be approximately $600 million in 2025, down 65% from 2024. These cash management actions provided a strategic benefit to the company’s cash position as the operating cash flow of $356 million grew by 57% from the prior year period.
Albemarle Corporation (NYSE:ALB) is an American specialty chemicals manufacturing company that offers a wide range of related products and services.
10. Arthur J. Gallagher & Co. (NYSE:AJG)
Number of Hedge Fund Holders: 49
5-Year Revenue Growth: 10.70%
Arthur J. Gallagher & Co. (NYSE:AJG) is among the best stocks to buy for the long term.
Wells Fargo analyst Elyse Greenspan trimmed her outlook on Arthur J. Gallagher & Co. (NYSE:AJG) on December 5, reducing the price target to $344 from $362 while sticking with an Overweight rating. The analyst also nudged EPS estimates lower, saying that the revision reflects the firm’s read on AJG’s expected Q4 2025 margins, as the company heads into its investor day on December 16.
In the meantime, Arthur J. Gallagher & Co. (NYSE:AJG) has been busy. The company has been on a steady acquisition run over the last couple of months, adding yet another deal on December 2, with its purchase of UK-based First Actuarial, a firm that specializes in pension administration, employee benefits, and investment services for employers and pension trustees across the UK. A few weeks earlier, in November, Gallagher took over Tompkins Insurance Agencies in Batavia, New York, which had been a wholly-owned unit of Tompkins Financial Corporation.
Arthur J. Gallagher & Co. (NYSE:AJG) had a strong third quarter. The company’s combined brokerage and risk management segments delivered a 20% total revenue growth, which marked its 19th consecutive quarter of double-digit top-line growth. Its incremental revenue from acquisitions was $450 million. In Q3, Gallagher closed six acquisitions, with an estimated annualized revenue of over $3 billion.
Arthur J. Gallagher & Co. (NYSE:AJG) is an American insurance brokerage, risk management, and consulting services firm that provides its services in approximately 130 countries globally.
9. Dover Corporation (NYSE:DOV)
Number of Hedge Fund Holders: 55
5-Year Revenue Growth: 5.08%
Dover Corporation (NYSE:DOV) is one of the best stocks to buy for the long term.
BNP Paribas Exane, on December 4, initiated its coverage on Dover Corporation (NYSE:DOV) with a Neutral rating and a $195 price target.
In separate news, the company’s SWEP subsidiary introduced new products to address the rising demand in data center cooling and district energy systems. The SWEP B327 and B224 are compact heat exchangers built to deliver a tight temperature approach. According to the company, this design makes them a strong match for the limited space inside data centers, where coolant distribution units are being used more often to manage high-density heat loads and keep servers at the right temperature.
On the financial side, Dover Corporation (NYSE:DOV) reported revenue of $2.1 billion in the third quarter of 2025, which was a 5% increase from the same period last year. The company said the improvement was driven by solid shipment growth in short-cycle components, ongoing strength across its longer-term growth markets, and meaningful contributions from recently closed acquisitions.
Dover Corporation (NYSE:DOV) is an American conglomerate that specializes in industrial products.
8. Cardinal Health, Inc. (NYSE:CAH)
Number of Hedge Fund Holders: 55
5-Year Revenue Growth: 8.19%
Cardinal Health, Inc. (NYSE:CAH) is among the best stocks to buy for the long term.
Barclays analyst Glen Santangelo initiated coverage of Cardinal Health, Inc. (NYSE:CAH) on December 9, giving the stock an Overweight rating and a $243 price target. The firm started its broader view of the US healthcare technology and distribution space on a neutral note. Within that coverage, Barclays is most optimistic about drug distributors, while its outlook on the dental and healthcare IT sub-sectors is more mixed.
Cardinal Health, Inc. (NYSE:CAH) has had a standout year. The stock has climbed nearly 68% since the start of 2025, a run that reflects the company’s ongoing transformation. By shifting its focus toward higher-margin areas of healthcare, particularly specialty pharmaceuticals and managed services, the company has seen a sharp improvement in earnings. In fiscal Q1 2026, revenue from the Pharmaceutical and Specialty Solutions segment rose 23% to $59.2 billion, helped by continued strength in brand and specialty drug sales from both existing and new customers.
Total revenue for the quarter reached $64 billion, which was up 22% from a year earlier. On November 3, the company also announced the completion of its acquisition of Solaris Health, the leading urology MSO in the country. Solaris adds more than 750 providers across more than 250 practice locations in 14 states, giving Cardinal Health’s Urology Alliance immediate scale within its multi-specialty MSO platform, The Specialty Alliance.
Cardinal Health, Inc. (NYSE:CAH) is one of the largest healthcare services and products companies in the US, supplying pharmaceuticals and medical equipment to a wide range of providers.
7. Colgate-Palmolive Company (NYSE:CL)
Number of Hedge Fund Holders: 56
5-Year Revenue Growth: 5.03%
Colgate-Palmolive Company (NYSE:CL) is one of the best stocks to buy for the long term.
On December 9, RBC Capital raised its rating on Colgate-Palmolive Company (NYSE:CL) to Outperform from Sector Perform while keeping the price target at $88. The analyst noted that the stock has been under pressure recently as slower global category growth has weighed on expectations for the company. Even so, the firm thinks 2026 will still be a challenging year, but believes estimates and expectations are “appropriately low.” RBC sees the setup as encouraging as Colgate works its way back toward its long-term growth goals.
In its earnings call for the third quarter of 2025, CEO Noel Wallace highlighted a volatile operating backdrop due to ongoing consumer uncertainty, tariffs, geopolitical issues, high cost inflation, and several other headwinds that have been affecting sales and profitability across the industry. Despite these challenges, he emphasized the company’s commitment to its 2030 Strategy. He also noted that Colgate-Palmolive Company (NYSE:CL) has healthy brands in categories that continue to grow, strong market share, a wide global presence with nearly half of its business coming from faster-growing emerging markets, and a highly efficient global supply chain to support that demand.
Colgate-Palmolive Company (NYSE:CL) updated its organic sales growth outlook to be roughly in line with the results so far this year, which suggests growth of around 1.2% for 2025. The figure also includes a 70 basis point hit from the company’s exit from private label. In addition, Colgate is a reliable dividend payer and has increased its dividends for 62 straight years.
Colgate-Palmolive Company (NYSE:CL) is a major American multinational consumer products company and a trusted leader in household and personal care goods.
6. Ecolab Inc. (NYSE:ECL)
Number of Hedge Fund Holders: 59
5-Year Revenue Growth: 5.44%
Ecolab Inc. (NYSE:ECL) is one of the best stocks to buy for the long term.
Ecolab Inc. (NYSE:ECL) announced on December 4 that it is raising its quarterly dividend by 12% to $0.73 per share. With this increase, the company’s indicated annual cash dividend for 2026 comes to $2.92 per share. This marks the 34th straight year that Ecolab has raised its dividend rate, and the company has now paid cash dividends for 89 years running, a record that highlights its long history of steady returns.
Christophe Beck, Ecolab’s Chairman and Chief Executive Officer, made the following comment on the dividend increase:
“The increase in Ecolab’s cash dividend underscores the strength of our business and our confidence in the future. Our robust cash flows, disciplined capital allocation, and strong balance sheet enable us to deliver superior shareholder returns while continuing to invest in innovation and growth. As we approach the end of another year of double-digit earnings growth, we remain focused on delivering strong and consistent shareholder value, fueled by our target of 12-15% growth in adjusted diluted earnings per share in 2026 and the years to come.”
In other news, Ecolab Inc. (NYSE:ECL) announced on November 4 its partnership with The Home Depot. The two companies are expanding their exclusive agreement, allowing Canadians to purchase products from the Ecolab Scientific Clean line for the first time. These cleaning solutions, which cover commercial, industrial, and residential needs, will now be available at over 180 Home Depot stores across Canada as well as online. The Canadian launch features nine products across several categories, including degreasers, bathroom cleaners, pressure wash concentrates, and floor care solutions.
Ecolab Inc. (NYSE:ECL) is a global sustainability leader that provides water, hygiene, and infection prevention solutions, helping protect people and the essential resources they rely on.
5. International Business Machines Corporation (NYSE:IBM)
Number of Hedge Fund Holders: 66
5-Year Revenue Growth: 5.01%
International Business Machines Corporation (NYSE:IBM) is one of the best stocks to buy for the long term.
On December 9, Stifel analyst David Grossman lifted his price target on International Business Machines Corporation (NYSE:IBM) to $325 from $295 after the company announced its plan to acquire Confluent for $11 billion in cash. He kept his Buy rating in place and noted that IBM has historically been able to get strong leverage out of companies that struggle to break into large enterprises and offer meaningful cost synergies. The analyst described the acquisition as a “solid deal” for IBM.
International Business Machines Corporation (NYSE:IBM) on December 8 announced that it is moving to buy Confluent, the data streaming platform, in an $11 billion deal transaction that includes debt. This is one of IBM’s largest deals to date and reflects a major push into enterprise software that supports real-time data needs for artificial intelligence tools. The Big Blue plans to pay $31 per share, and Bloomberg’s calculation of Confluent’s Class A and Class B shares put the equity value of the offer at roughly $10.9 billion.
Both companies expect the deal to close by mid-2026. If the transaction does not go through or is terminated, International Business Machines Corporation (NYSE:IBM) will owe Confluent a breakup fee of $453.6 million, according to the regulatory filing that accompanied the announcement.
International Business Machines Corporation (NYSE:IBM) is one of the leading American multinational tech companies, widely known for its hybrid cloud platform, AI capabilities, consulting services, and a broad range of enterprise software and hardware.
4. CSX Corporation (NASDAQ:CSX)
Number of Hedge Fund Holders: 75
5-Year Revenue Growth: 5.12%
CSX Corporation (NASDAQ:CSX) is one of the best stocks to buy for the long term.
On December 8, Morgan Stanley raised its price target on CSX Corporation (NASDAQ:CSX) to $30 from $27 while maintaining an Equal Weight rating on the shares. The firm adjusted several ratings and targets across the freight transportation group as part of its 2026 outlook. It also upgraded its view of the overall freight transportation industry to Attractive from In Line for the coming year. According to the analyst, risk and reward levels look better than they have since 2020, even if the “coast is not entirely clear.”
CSX Corporation (NASDAQ:CSX) third-quarter earnings showed mixed trends. The company’s volumes reached 1.61 million units, up 1% from the same quarter of 2024 and 2% higher than the previous quarter. Revenue for the period came in at $3.59 billion, down 1% YoY. The company pointed out that lower export coal prices and softer merchandise volume weighed on results, but stronger pricing in merchandise, growth in intermodal shipments, and higher revenue from other categories helped cushion the decline.
That said, operational metrics were a bright spot. CSX Corporation (NASDAQ:CSX) reported its fastest train velocity since early 2021. Dwell time reached its lowest level since mid-2023, and the number of average daily cars online fell to its lowest point since 2020. Management also highlighted that the Howard Street Tunnel and Blue Ridge subdivision projects were completed ahead of schedule, adding that both will boost capacity and resilience moving forward.
CSX Corporation (NASDAQ:CSX) is a leading transportation company that provides rail service, intermodal options, and rail-to-truck transload solutions for customers across a wide range of markets.
3. AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 93
5-Year Revenue Growth: 11.60%
AbbVie Inc. (NYSE:ABBV) is among the best stocks to buy for the long term.
On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price target, which reflects a 29.6% upside from its current levels.
Over the years, AbbVie Inc. (NYSE:ABBV) has built an impressive line-up of top-selling drugs. Skyrizi, an immunology treatment for arthritis and psoriasis, recorded a 46.8% growth in its sales in the third quarter of 2025 to $4.7 billion. Rinvoq, another immunology drug, reported $2.18 billion in sales, up 35.3% YoY. Similarly, Humira, which is used to treat plaque psoriasis, posted $993 million in revenues, which showed a staggering 55.4% growth from the previous year.
Due to these exceptional results, AbbVie Inc. (NYSE:ABBV)’s management sees further growth in these drugs’ performance. The company expects Rinvoq to generate $11 billion in revenues by 2027, with Skyrizi projected to reach $20 billion. Though the guidance looks overly ambitious, the company’s strong portfolio and its efforts to expand its pipelines through acquisitions make it achievable. In addition, AbbVie Inc. (NYSE:ABBV)’s pipeline across multiple therapeutic areas is promising as well.
On October 31, AbbVie Inc. (NYSE:ABBV)’s board raised the quarterly dividend by 5.5% to $1.73 per share, up from $1.64. That brings the annual payout to $6.92 per share and marks the company’s 53rd consecutive year of dividend growth.
AbbVie Inc. (NYSE:ABBV) is an American pharmaceutical company known for producing treatments that address a wide range of medical conditions.
2. Johnson & Johnson (NYSE:JNJ)
Number of Hedge Fund Holders: 103
5-Year Revenue Growth: 5.91%
Johnson & Johnson (NYSE:JNJ) is one of the best stocks to buy for the long term.
On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm reviewed the company’s model and noted “multiple drivers of additional upside” going into 2026.
In addition to being a strong pharmaceutical company, Johnson & Johnson (NYSE:JNJ) is also taking strategic steps to enhance its operations. In October, the company announced plans to separate its orthopedics division as a standalone company named DePuy Synthes within 18-24 months. Previously, JNJ also spun off its consumer healthcare division, which now operates as Kenvue. These key initiatives are part of the company’s plan to focus on more high-growth areas to broaden its reach.
In addition, Johnson & Johnson (NYSE:JNJ)’s announcement to acquire Halda Therapeutics for $3.05 billion is also a step to strengthen its already extensive portfolio of oncology drugs. It will also help encounter some of the competitive pressure it is facing in its oncology and immunology portfolio, including drugs like Tremfya. JNJ’s competitors, including AbbVie, offer comparable treatments and have been steadily capturing market shares from JNJ.
1. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 114
5-Year Revenue Growth: 17.18%
Eli Lilly and Company (NYSE:LLY) is among the best stocks to buy for the long term.
Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move could increase pressure on rival companies.
Being included in the national reimbursement list makes a drug more accessible to China’s 1.4 billion population. However, while sales volume may rise, lower prices often offset some of the revenue gains.
Mounjaro, a once-weekly injectable therapy, was launched in China in January this year, following the introduction of Ozempic, a similar diabetes treatment from Danish rival Novo Nordisk. Eli Lilly and Company (NYSE:LLY) said the final reimbursement prices for Mounjaro will be determined by the National Healthcare Security Administration’s official announcement. The NHSA did not immediately respond to requests for pricing details.
Eli Lilly and Company (NYSE:LLY) is a major American pharmaceutical company that develops medicines and treatments for serious conditions.
While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 11 Worst Performing Dividend Stocks Year-to-Date.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
